MIRA Pharmaceuticals Stock (NASDAQ:MIRA)

Ownership Financials Chart

Previous Close

$0.98

52W Range

$0.90 - $2.45

50D Avg

$1.03

200D Avg

$1.29

Market Cap

$41.19M

Avg Vol (3M)

$152.86K

Beta

1.44

Div Yield

MIRA Company Profile

MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.

Industry

Drug Manufacturers - General

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Aug 14, 2023

Website

MIRA Performance

MIRA Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	-	$-8.02M	$-8.53M
Net Income	$-32.00M	$-7.85M	$-11.98M
EBITDA	-	$-8.02M	$-8.53M
Basic EPS	$-1.35	$-0.51	$-0.65
Diluted EPS	$-1.35	$-0.51	$-0.65

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
POCI	Precision Optics Corporation, Inc.
QTTB	Q32 Bio Inc.
MODD	Modular Medical, Inc.
ANTX	AN2 Therapeutics, Inc.
TLPH	Talphera, Inc.